Compare BIO-TECHNE Corp (TECH) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Total World Stock Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Vanguard Total World Stock Index Fund ETF trades at $160.66. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| TECH | VT | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.48 | $162.39 |
52-Week Low | $43.31 | $134.19 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
VT trades at $160.92, down 0.5% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF offers broad global equity diversification with over 10,000 stocks and a low 0.06% expense ratio. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced holdings.
The outlook remains favorable for long-term investors seeking global exposure, supported by cost efficiency and diversification benefits. Risks include trade policy uncertainty and market volatility, but VT's structure mitigates single-country or sector risks. Analyst sentiment is generally positive, emphasizing its role as a core holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
